RecruitingPhase 2NCT06348134

Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

Assessing the Efficacy and Safety of Optimal Neoadjuvant to Adjuvant Anti-HER2- Based Therapy in Nigerian Women With HER2+ Breast Cancer

Sponsor

University of Chicago

Enrollment

74 participants

Start Date

Mar 18, 2025

Study Type

INTERVENTIONAL

Conditions

Breast Cancer HER2-positive Breast Cancer Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

Summary

Doctors leading this study would like to learn about providing cancer treatment/therapies to Nigerian women with breast cancer based on their human epidermal growth factor receptor 2 (HER2) status. This study will focus on the efficacy and safety of anti-HER2 cancer treatment before and after surgery.

Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This trial assesses the efficacy and safety of anti-HER2 targeted therapy (treatment directed at a specific protein found on certain breast cancer cells) in Nigerian women with HER2-positive breast cancer, both before and after surgery. It aims to make these treatments more accessible and studied in African healthcare settings. **You may be eligible if...** - You are a woman between 18 and 70 years old - You have been diagnosed with HER2-positive breast cancer, confirmed by biopsy - Your tumor is at least 2 cm and measurable by ultrasound - Your cancer is at stage 2A to 3C - You have not yet received chemotherapy for this cancer - You are not currently pregnant or nursing **You may NOT be eligible if...** - You are HER2-negative - You have already received chemotherapy for this cancer - You are pregnant or breastfeeding without willingness to use contraception - Your physical performance level is very poor (ECOG score 4) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTrastuzumab emtansine

A chemotherapy drug.

DRUGPertuzumab Injection

A prescription medicine that is approved for use in combination with trastuzumab and docetaxel in people who have HER2-positive breast cancer that has spread to different parts of the body (metastatic) and who have not received anti-HER2 therapy or chemotherapy for metastatic breast cancer.

DRUGDocetaxel

A chemotherapy drug.

DRUGTamoxifen

A medication used to treat breast cancer.

DRUGLetrozole

A medication used to treat breast cancer.

DRUGGoserelin

A hormone therapy drug.